|0.37|| +0.0688 / +22.84%|
iBio, Inc. operates as a biotechnology company, which focuses on commercializing its proprietary technology, iBioLaunch and iBioModulator, and developing product candidates derived from these platforms. iBioLaunch is a proprietary, transformative platform technology for development and production of biologics using transient gene expression in hydroponically grown, unmodified green plants. iBioModulator is a proprietary technology platform that is designed to improve the potency and duration of effect of both prophylactic and therapeutic vaccines produced with any recombinant expression technology including iBioLaunch. The company was founded on April 15, 1993 and is headquartered in Newark, DE.
|Robert B. Kay||Executive Chairman & Chief Executive Officer|
|Robert L. Erwin||President|
|James P. Mullaney||Chief Financial Officer|
|Terence E. Ryan||Chief Scientific Officer|
|Douglas C. Hicks||Senior VP-Business Development & Strategy|